Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-/Adjuvant EIA Chemotherapy in High-risk Soft Tissue Sarcoma
NCT01382030Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Jun 2005
- Primary completion
- Sep 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, ifosfamide, pegylated liposomal doxorubicin in soft tissue sarcoma (STS), sponsored by Heidelberg University. Started Jun 2005; status: completed.
02
Drugs
etoposideifosfamidepegylated liposomal doxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01382030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01382030.